Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia
- PMID: 27138956
- DOI: 10.1007/s40266-016-0375-0
Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia
Abstract
It has been established that diabetes mellitus (DM) is a risk factor for dementia, and recent studies have clearly shown that dementia is one of the complications of DM. The increase of cognitively impaired subjects with the progression of aging in the population is an urgent worldwide issue. Due to the pharmacological advancement in the field of DM, we now have many kinds of antidiabetic medications with a wide variety of mechanisms of action and characteristics. It is a good time to review the characteristics of each antidiabetic medication and the evidence related to their prevention of cognitive dysfunction or preservation of cognition. The available data on the effects of antidiabetics on cognitive dysfunction and dementia show that several of the antidiabetics have the potential to improve cognition. The accumulation of more data to determine the best ways to use antidiabetics in order to prevent cognitive impairment would be warranted. To this end, the present review will try to illustrate the horizon of achievement in this field.
Similar articles
-
Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study.Diabetes Care. 2020 Nov;43(11):2691-2701. doi: 10.2337/dc20-0892. Epub 2020 Sep 23. Diabetes Care. 2020. PMID: 32967921
-
Conversion of mild cognitive impairment to dementia among subjects with diabetes: a population-based study of incidence and risk factors with five years of follow-up.J Alzheimers Dis. 2015;43(4):1441-9. doi: 10.3233/JAD-141566. J Alzheimers Dis. 2015. PMID: 25159674
-
Elevated Fasting Blood Glucose Level Increases the Risk of Cognitive Decline Among Older Adults with Diabetes Mellitus: The Shanghai Aging Study.J Alzheimers Dis. 2019;67(4):1255-1265. doi: 10.3233/JAD-180662. J Alzheimers Dis. 2019. PMID: 30689569
-
[Diabetes mellitus and cognitive disorders from the diabetologists perspective].Vnitr Lek. 2017 Fall;63(10):717-720. Vnitr Lek. 2017. PMID: 29127756 Review. Czech.
-
New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease.Metab Brain Dis. 2018 Aug;33(4):1009-1018. doi: 10.1007/s11011-018-0227-1. Epub 2018 Apr 6. Metab Brain Dis. 2018. PMID: 29626315 Review.
Cited by
-
Association between exenatide use and incidence of Alzheimer's disease.Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12139. doi: 10.1002/trc2.12139. eCollection 2021. Alzheimers Dement (N Y). 2021. PMID: 33614900 Free PMC article.
-
Lipoprotein-associated Phospholipase A2 Is Associated with Risk of Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes.Sci Rep. 2017 Sep 26;7(1):12311. doi: 10.1038/s41598-017-12515-z. Sci Rep. 2017. PMID: 28951620 Free PMC article.
-
Relationships between Cognitive Function and Odor Identification, Balance Capability, and Muscle Strength in Middle-Aged Persons with and without Type 2 Diabetes.J Diabetes Res. 2021 Oct 7;2021:9961612. doi: 10.1155/2021/9961612. eCollection 2021. J Diabetes Res. 2021. PMID: 34660814 Free PMC article.
-
Regulation of Diabetes: a Therapeutic Strategy for Alzheimer's Disease?J Korean Med Sci. 2019 Dec 2;34(46):e297. doi: 10.3346/jkms.2019.34.e297. J Korean Med Sci. 2019. PMID: 31779058 Free PMC article. Review.
-
Metabolic Profiling of Female Tg2576 Mouse Brains Provides Novel Evidence Supporting Intranasal Low-Dose Pioglitazone for Long-Term Treatment at an Early Stage of Alzheimer's Disease.Biomedicines. 2020 Dec 9;8(12):589. doi: 10.3390/biomedicines8120589. Biomedicines. 2020. PMID: 33317213 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical